Biotie has changed its strategy of focusing on locomotive diseases to fibrotic diseases. Biotie Therapies and Seikagaku have agreed to terminate their license agreement for Biotie’s VAP-1 antibody ...
FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...
Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease Biotie announced today that it maintains global development and ...
Weston said, "We believe that VAP-1 remains a viable target in inflammatory and fibrotic disease given the wealth of evidence in other preclinical models, and the use of small molecule inhibitors of ...
Please provide your email address to receive an email when new articles are posted on . Terns Pharmaceuticals Inc. announced initiation of a phase 1b clinical trial assessing TERN-201 for the ...
Roche (SIX: RO, ROG: OTCQX: RHHBY) and Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd., today announced a worldwide agreement for the further ...
SEOUL, Korea & NANJING, China--(BUSINESS WIRE)--LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results